Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

Ph+ ALL in 2022: is there an optimal approach?

“…10 Additional stud ies sup port this fi nd ing, with Ph + ALL with IKZF1 plus alter ations (IKZF1 dele tions with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG dele tion 16 ) appearing to be par tic u larly resis tant to ther apy. [17][18][19][20] In addi tion, dele tions in CDKN2A/2B have been asso ci ated with a poor prog no sis after allo ge neic hema to poi etic cell trans plan ta tion (HCT) in first com plete response (CR) due to a high relapse rate. 21 Conversely, long dele tions of MEF2C and K-Ras have been asso ci ated with improved CR rate and, in the case of MEF2C, improved dis ease-free sur vival.…”